سعر تامسولين بلس 6/0.4مجم ام ار 20 قرص 2024

Fixed-dose modified-release tablets of solifenacin 6 mg and tamsulosin 0.4 mg (20 tablets) marketed in Egypt for urinary symptoms of benign prostatic hyperplasia.

• Moderate to severe storage symptoms (urgency, increased frequency) and voiding symptoms associated with BPH in men not adequately responding to monotherapy.Population: Adult menelectronic medicines compendium (emc)

• Most frequent: dry mouth (9.5%), constipation (3.2%), dyspepsia (2.4%); also dizziness, blurred vision, fatigue, ejaculation disorder; acute urinary retention (0.3%) is the most serious.International label, same formulation · electronic medicines compendium (emc)

• Hypersensitivity to the active substances or excipients; haemodialysis; severe hepatic impairment.International label, same formulation · electronic medicines compendium (emc)
• Severe renal impairment or moderate hepatic impairment together with a strong CYP3A4 inhibitor (e.g. ketoconazole).International label, same formulation · electronic medicines compendium (emc)
• Severe gastrointestinal conditions (including toxic megacolon), myasthenia gravis, narrow-angle glaucoma or risk of these; history of orthostatic hypotension.International label, same formulation · electronic medicines compendium (emc)

• Use with caution in severe renal impairment, risk of urinary retention, GI obstruction or decreased motility, hiatus hernia/reflux, autonomic neuropathy.International label, same formulation · electronic medicines compendium (emc)
• QT prolongation and torsade de pointes have been observed with solifenacin in patients with risk factors; angioedema and anaphylaxis reported.International label, same formulation · electronic medicines compendium (emc)
• Orthostatic hypotension and rarely syncope; Intraoperative Floppy Iris Syndrome during cataract/glaucoma surgery.International label, same formulation · electronic medicines compendium (emc)

• Moderate/strong CYP3A4 inhibitors (e.g. verapamil, ketoconazole, ritonavir, itraconazole)Limit to one tablet daily and use with caution; avoid strong CYP3A4 inhibitors in CYP2D6 poor metabolisers or with strong CYP2D6 inhibitors.electronic medicines compendium (emc)
• Other anticholinergic medicinesMay give more pronounced therapeutic and undesirable effects.electronic medicines compendium (emc)

• Not indicated for use in women.International label, same formulation · electronic medicines compendium (emc)

• Solifenacin: Competitive muscarinic receptor antagonist reducing bladder storage symptoms.
• Tamsulosin: Blocks alpha-1A/1D adrenoceptors, relaxing prostatic smooth muscle.